Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Mabwell (Shanghai) Bioscience Co., Ltd.
邁威(上海)生物科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2493)

APPOINTMENT OF MEMBERS OF SENIOR MANAGEMENT

The board (the "**Board**") of directors (the "**Directors**") of Mabwell (Shanghai) Bioscience Co., Ltd. (the "**Company**") hereby announces that, pursuant to the Articles of Association of the Company and the relevant rules and regulations, the third session of the Board resolved to appoint Dr. Liu Datao (劉大濤) as general manager, Dr. Wu Hai (武海) as deputy general manager, Mr. Hua Jun (華俊) as deputy general manager and chief financial officer, Dr. Gui Xun (桂勛) as deputy general manager, Dr. Wang Shuhai (王樹海) as deputy general manager, Mr. Hu Huiguo (胡會國) as deputy general manager, Mr. Li Han (李瀚) as deputy general manager, Mr. Ni Hua (倪華) as deputy general manager, Ms. Chen Xi (陳曦) as deputy general manager, Ms. Yu Shanshan (余珊珊) as deputy general manager, and Ms. Wang Hefei (王鶴飛) as secretary of the Board. Their terms of office shall commence on June 18, 2026 until the expiry of the term of the third session of the Board.

Pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Stock Exchange**"), biographical details of the members of senior management required to be disclosed are set out as follows:

Dr. LIU Datao (劉大濤), aged 54, is the chairman of the Board, an executive Director and the general manager of our Company and is primarily responsible for overall strategic planning, business direction and operational management of our Group. Dr. Liu was appointed as a Director in April 2019 and was re-designated as an executive Director in December 2024, and he was appointed as the chairman of our Board in June 2023. He served as our president from July 2017 to April 2019 and has been the general manager of our Company since April 2019. Dr. Liu also currently serves as executive director and general manager of various subsidiaries of our Company.

Dr. Liu has approximately 24 years of working and management experience in the pharmaceutical industry. From July 2000 to October 2000, Dr. Liu was a researcher at Shanghai Laishi Blood Products Co., Ltd. (上海萊士血製品有限公司) (currently known as "Shanghai RAAS Blood Products Co., Ltd. (上海萊士血液製品股份有限公司)", a company listed on the Shenzhen Stock Exchange, stock code: 002252). He served as a deputy head of research institute and the director of biology department at Shanghai Xinyi Pharmaceutical Co., Ltd. (上海信誼藥廠有限公司) (currently known as "Shanghai Sine Pharmaceutical Laboratories Co., Ltd. (上海上藥信誼藥廠有限公司)") under Shanghai Pharmaceuticals Holding Co., Ltd. (上海醫藥集團股份有限公司) (a company listed on the Hong Kong Stock Exchange (stock code: 2607) and Shanghai Stock Exchange, stock code: 601607) from November 2000 to December 2010. Dr. Liu acted as the deputy head of the central research institute, research and development director and head of the biopharmaceuticals research department at Shanghai Pharmaceuticals Holding Co., Ltd. from January 2011 to June 2017, and as the general manager of its wholly-owned subsidiary Shanghai Jiaolian Pharmaceutical Research and Development Co., Ltd. (上海交聯藥物研發有限公司) (currently known as "Shanghai Shangyao Cross Linked Pharmaceutical Technology Co., Ltd. (上海上藥交聯醫藥科技有限公司)") from February 2014 to June 2017.

Dr. Liu received his bachelor's degree and master's degree in biochemistry from Jilin University (吉林大學) in the PRC in July 1993 and June 1996, respectively, and doctorate degree in medical chemistry from Shenyang Pharmaceutical University (瀋陽藥科大學) in the PRC in July 2000. Dr. Liu was qualified as a senior engineer by the Shanghai Engineering Series Senior Professional Title Evaluation Committee (Industrial Production Category) (上海市工程系列正高級職稱評審委員會(工業生產類)) of the Shanghai Municipal Human Resources and Social Security Bureau (上海市人力資源和社會保障局) in December 2022.

Dr. Liu Datao is the beneficial owner of 15,100,000 A shares and indirectly holds 6,360,000 A shares of the Company through Ningbo Meishan Free Trade Port Zhongjun Jianlong Investment Partnership (Limited Partnership) (寧波梅山保税港區中駿建隆投資合夥企業(有限合夥)).

Dr. WU Hai (武海), aged 53, is an executive Director, deputy general manager and the research and development president of our Company and is primarily responsible for overseeing research and development activities and global business development. Dr. Wu was appointed as the research and development president of our Company in November 2023 and was appointed as deputy general manager and executive Director of our Company in December 2024. Dr. Wu has served as a director of Beijing Kohnoor Science & Technology Co., Ltd. (北京科諾信誠科技有限公司) since August 2024, and a director of Shanghai PUREmab Bio-Tech Co., Ltd. (上海普銘生物科技有限公司) since July 2024.

From March 2003 to September 2007, Dr. Wu was a postdoctoral fellow in life medicine at Stanford University. Dr. Wu served as a researcher at Trellis Bioscience from August 2007 to February 2009. Dr. Wu then served as a senior researcher at Amgen from February 2009 to May 2013. Dr. Wu was the chief science officer of TopAlliance Biosciences from May 2013 and March 2015. He worked at Junshi as a deputy general manager from March 2015 to October 2020, as a financial director from March 2015 to June 2018, as an executive director from December 2016 to October 2020 and as a non-executive director from October 2020 to August 2023.

Dr. Wu received his bachelor's degree in biochemistry from Nanjing University (南京大學) in PRC in July 1994 and doctorate degree in genetics and development from the University of Texas Southwestern Medical Center in the U.S. in May 2002. Dr. Wu completed his postdoctoral studies in life medicine in Stanford University in the U.S. in September 2007.

Mr. HUA Jun (華俊), aged 44, is an executive director, a deputy general manager and the chief financial officer of our Company and is primarily responsible for overall financial management of our Group. Mr. Hua has been our deputy general manager and the chief financial officer of our Company since June 2023. From September 2004 to January 2008, Mr. Hua served as a finance officer at General Electric Company (通用電氣有限公司). From February 2008 to February 2011, Mr. Hua served as the finance manager of orthopedic department at Johnson & Johnson Medical (Shanghai) Ltd. (強生(上海)醫療器材有限公司), a subsidiary of Johnson & Johnson, a company listed on the New York Stock Exchange (stock ticker: JNJ). From September 2011 to December 2018, Mr. Hua served as the senior financial control manager of China prescription drugs and the head of finance for APAC pharmaceutical development at Shanghai Roche Pharmaceutical Ltd. (上海羅氏製藥有限公司). From January 2019 to August 2019, he served as a vice president of finance at Hutchison MediPharma Co., Ltd. (和記黃埔醫藥(上海) 有限公司). From August 2019 to May 2023, Mr. Hua served as the general manager of finance department and purchasing department at Shanghai Henlius Biotech, Inc. (上海復宏漢霖生物技術股份有限公司) (a company listed on the Hong Kong Stock Exchange, stock code: 2696).

Mr. Hua received his bachelor's degree in finance from Shanghai University (上海大學) in the PRC in June 2004, and master's degree in business administration from Tongji University (同濟大學) in the PRC in June 2011. He was qualified as a certified public accountant in the U.S. in January 2016 and in Australia in May 2021. Mr. Hua has also obtained qualifications as a certified management accountant from the Institute of Management Accountants United States of America in September 2012, certification in risk management assurance from the Institute of Internal Auditors in May 2013, certification in control self-assessment and certified internal auditor from the Institute of Internal Auditors in November 2013, certified information systems auditor from the ISACA in February 2016, fellow of the Institute of Financial Accountants on March 2017, fellow of the Institute of Public Accountants on March 2017, chartered management accountant and chartered global management accountant from the Chartered Institute of Management Accountants in July 2017, board secretary qualification from the Shanghai Stock Exchange in December 2020, and certified lean six sigma black belt from the Global Association for Quality Management in January 2023. Mr. Hua is currently an associate of the Chartered Institute of Arbitrators and a member of the Forensic Certified Public Accountants Association.

Dr. GUI Xun (桂勛), aged 40, is an executive Director (employee representative Director) and a deputy general manager of our Company and is primarily responsible for overseeing early innovation research and molecular discovery. Dr. Gui was elected as an employee representative Director in December 2025. He has been our deputy general manager since June 2023. He also worked in our Company as the research assistant of the president from June 2019 to February 2023, a senior director and the head of the innovation and discovery department from September 2020 to February 2023 and a vice president since March 2023.

From January 2015 to May 2019, Dr. Gui worked at the University of Texas Health Science Center at Houston in the U.S. as a postdoctoral researcher. Dr. Gui received his bachelor's degree in biotechnology from Hunan University (湖南大學) in the PRC in June 2007. He obtained his master's degree in cell biology and doctorate degree in biochemistry and molecular biology from Xiamen University (廈門大學) in the PRC in September 2010 and June 2014, respectively. Dr. Gui completed his postdoctoral studies in tumor immunology and antibody drug development from the University of Texas Health Science Center at Houston in the U.S. in May 2019. He has been a director of the subsidiaries of the Company including Lianwei Chuanghe (Shanghai) Biotechnology Co., Ltd. (聯威創合(上海)生物技術有限公司) since March 2026 and Lianwei Chuangyuan (Shanghai) Biotechnology Co., Ltd. (聯威創源(上海)生物技術有限公司) since November 2025.

Dr. Gui indirectly holds 500,000 A shares of the Company through Ningbo Meishan Free Trade Port Zhenzhu Investment Management Partnership (Limited Partnership) (寧波梅山保稅港區真珠投資管理合夥企業(有限合夥)).

Dr. WANG Shuhai (王樹海), aged 51, is a deputy general manager of our Company and is primarily responsible for overseeing clinical trial design and operation management. Dr. Wang has been our deputy general manager since July 2017.

Between August 2004 to June 2013, Dr. Wang served successively as the head of the medical registration department, the head of the project management department, an assistant to the head of research institute and medical director at Shanghai Xinyi Pharmaceutical Co., Ltd. (上海信誼藥廠有限公司) (currently known as "Shanghai Sine Pharmaceutical Laboratories Co., Ltd. (上海上藥信誼藥廠有限公司)"). From July 2013 to July 2017, Dr. Wang served successively as a senior researcher, an assistant to the director and the head of clinical research center at Fosun Pharma Research Institute (復星醫藥研究院).

Dr. Wang received his bachelor's degree in traditional Chinese medicine and master's degree in internal medicine from Shandong University of Traditional Chinese Medicine (山東中醫藥大學) in the PRC in July 1998 and July 2001, respectively, and his doctorate degree in integrated Chinese and Western clinical medicine from Fudan University (復旦大學) in the PRC in July 2004. Dr. Wang was qualified as a senior engineer (professor level) by the Ministry of Human Resources and Social Security of the PRC (中國國家人力資源和社會保障部) in December 2014.

Dr. Wang is the beneficial owner of 400,000 A shares and indirectly holds 2,000,000 A shares of the Company through Ningbo Meishan Free Trade Port Zhenzhu Investment Management Partnership (Limited Partnership) (寧波梅山保稅港區真珠投資管理合夥企業(有限合夥)).

Mr. HU Huiguo (胡會國), aged 48, is a deputy general manager of our Company and the secretary of the Board, and is primarily responsible for business operations (including international business), capital management, investor relations, legal and company secretarial matters of our Group. Mr. Hu was appointed as a Director in May 2021 and was re-designated as an executive Director from December 2024 to June 2026. He has been our deputy general manager since February 2020, and he acted as our secretary of the Board since June 2020.

From August 2005 to June 2012, Mr. Hu held several positions at Shanghai Xinyi Pharmaceutical Co., Ltd (上海信誼藥廠有限公司) (currently known as "Shanghai Sine Pharmaceutical Laboratories Co., Ltd. (上海上藥信誼藥廠有限公司)"), including GMP internal auditor of the quality supervision department, assistant director of the preparation workshop of the pharmaceutical factory, deputy head of research institute, and head of international department. Mr. Hu served as the business development director and as general manager of the overseas business department at Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (三生國健藥業(上海)股份有限公司) (a company listed on the Shanghai Stock Exchange STAR Market, stock code: 688336) from June 2012 to March 2016, during which Mr. Hu also served as the general manager at CN-GEN MAB CO., LIMITED (中健抗體有限公司) (a wholly-owned Hong Kong subsidiary of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (三生國健藥業(上海)股份有限公司)) from March 2014 to March 2016 and the general manager of the international marketing business department of pharmaceutical products within the group of 3SBio Inc. (三生製藥) (a company listed on the Hong Kong Stock Exchange, stock code: 1530) from March 2016 to January 2020.

Mr. Hu received his bachelor's degree in (Japanese) pharmaceutical science and his master's degree in pharmaceutical preparations from Shenyang Pharmaceutical University (瀋陽藥科大學) in the PRC in July 2002 and July 2005, respectively. Mr. Hu was qualified as an engineer by Shanghai Pharmaceutical (Group) Limited (上海醫藥(集團)有限公司) in December 2008 and obtained a board secretary qualification from the Shanghai Stock Exchange in December 2020.

Mr. Hu indirectly holds 2,000,000 A shares of the Company through Ningbo Meishan Free Trade Port Zhongjun Jianlong Investment Partnership (Limited Partnership) (寧波梅山保税港區中駿建隆投資合夥企業(有限合夥)).

Mr. LI Han (李瀚), aged 54, is a deputy general manager of our Company and is primarily responsible for overseeing domestic marketing and business. Mr. Li served as our vice president from July 2020 to September 2020 and has been our deputy general manager since September 2020. Mr. Li has also been serving as general manager of Jiangsu Mabwell from July 2021 and as director and general manager of Shanghai Junshikang from December 2021. Mr. Li has served as a director of Chongqing Bochuang Pharmaceutical Co., Ltd. (重慶博創醫藥有限公司) since August 2024 and a director of MabwellVision (Shanghai) Bio-Tech Co., Ltd. (邁威視(上海)生物科技有限公司) since May 2026.

From February 2003 to September 2018, Mr. Li worked at Sanofi (China) Investment Co., Ltd. (賽諾菲(中國)投資有限公司), where his last position held was national director. Mr. Li then served as a vice president and the general manager of the marketing department at Beijing Tide Pharmaceutical Co., Ltd. (北京泰德製藥股份有限公司) from September 2018 to March 2019. From September 2019 to April 2020, Mr. Li served as a vice president and a deputy general manager at Sichuan Kelun Pharmaceutical Co., Ltd. (四川科倫藥業股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 002422).

Mr. Li received his associate degree in clinical medicine from Tianjin Medical College (天津醫學院) (currently known as "Tianjin Medical University (天津醫科大學)") in the PRC in July 1993, bachelor's degree in clinical medicine from Tianjin Medical University (天津醫科大學) in the PRC in July 1999.

Mr. Li indirectly holds 300,000 A shares of the Company through Ningbo Meishan Free Trade Port Zhongjun Jianlong Investment Partnership (Limited Partnership) (寧波梅山保税港區中駿建隆投資合夥企業(有限合夥)).

Mr. NI Hua (倪華), aged 55, is a deputy general manager of our Company and is primarily responsible for overseeing industrialization and construction. Mr. Ni has been our deputy general manager since September 2020. Mr. Ni has also been serving as manager of Maiwei Lishui since December 2021 and currently serves as director of Feifan (Chongqing) Biopharmaceutical Co., Ltd. (非凡(重慶)生物製藥有限責任公司). Mr. Ni has served as a director of Shanghai Langrun Mabwell Biomedical Technology Co., Ltd (上海朗潤邁威生物醫藥科技有限公司) since April 2025.

Between 2002 and 2018, Mr. Ni successively served as project manager, chief engineer, and the general manager of the engineering management department at Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (三生國健藥業(上海)股份有限公司) (a company listed on the Shanghai Stock Exchange STAR Market, stock code: 688336). From July 2019 to August 2022, he worked at Shanghai National Engineering Research Center of Antibody Medicine Co., Ltd. (上海抗體藥物國家工程研究中心有限公司) as a manager. Mr. Ni then served as deputy general manager at Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. from June 2019 to September 2020.

Mr. Ni received his bachelor's degree in biochemistry from Anhui University (安徽大學) in the PRC in July 1994 and was qualified as a senior engineer by Ministry of Human Resources and Social Security of the PRC (國家人力資源和社會保障部) in November 2011.

Mr. Ni indirectly holds 400,000 A Shares of the Company through Ningbo Meishan Free Trade Port Zhenzhu Investment Management Partnership (Limited Partnership)(寧波梅山保税港區真珠投資管理合夥企業(有限合夥)).

Ms. CHEN Xi (陳曦), aged 46, is a deputy general manager of our Company and is primarily responsible for overseeing human resources, training, and general management (including public relations, governmental relations, and administration). Ms. Chen has been our deputy general manager since January 2021.

Ms. Chen served successively as the key account manager and strategic market manager in China at Thermo Fisher Scientific (China) Co., Ltd. (賽默飛世爾科技(中國)有限公司) from April 2009 to July 2014. From July 2014 to June 2015, Ms. Chen served as business development manager in China at Roche Diagnostics Products (Shanghai) Co., Ltd. (羅氏診斷產品(上海)有限公司). From August 2015 to July 2016, she served as the sales director and the business development manager in Greater China at Hangzhou Yizhen Biotechnology Co., Ltd. (杭州奕真生物科技有限公司). Ms. Chen then served as the national sales director of GE Medical Systems Trade & Development (Shanghai) Co., Ltd. (通用電氣醫療系統發展(上海)有限公司) from July 2016 to October 2019. She also served as the head of sales in Greater China of Illumina (China) Scientific Co., Ltd. (因美納(中國)科學器材有限公司) from October 2019 to January 2021.

Ms. Chen received her bachelor's degree in bioengineering from Heilongjiang University (黑龍江大學) in the PRC in July 2003, master's degree in biochemistry and molecular biology from Jilin University (吉林大學) in the PRC in June 2006 and master's degree in business administration from Shanghai Jiao Tong University (上海交通大學) in the PRC in June 2011.

Ms. Chen indirectly holds 300,000 A shares of the Company through Ningbo Meishan Free Trade Port Zhongjun Jianlong Investment Partnership (Limited Partnership) (寧波梅山保税港區中駿建隆投資合夥企業(有限合夥)).

Ms. Yu Shanshan (余珊珊), aged 46, is a deputy general manager of our Company and holds a Ph.D. in Biophysics. From September 2010 to March 2012, she served as a staff member at the Anhui Pharmaceutical Professional and Technical Personnel Qualification Certification Center. From April 2012 to February 2015, she served as a reviewer at the Anhui Provincial Drug Evaluation and Inspection Center. From February 2015 to June 2021, she served as a reviewer at the Center for Drug Evaluation of the National Medical Products Administration. From June 2021 to the present, she has successively served as senior director of the registration department, assistant to the president, and vice president of the Company, fully responsible for registration and pharmacovigilance.

Ms. Yu indirectly holds 300,000 A shares of the Company through Ningbo Meishan Free Trade Port Zhongjun Jianlong Investment Partnership (Limited Partnership) (寧波梅山保税港區中駿建隆投資合夥企業(有限合夥)).

Ms. WANG Hefei (王鶴飛), aged 36, was appointed as our joint company secretary in December 2024 (effective from January 2025). Ms. Wang has been the head of our securities department since August 2019 and our securities representative since June 2020. She joined the Group in September 2018 and served as our supervisor of the department of project management from September 2018 to July 2019. Prior to joining our Group, Ms. Wang worked in Shanghai Qingrun Pharmaceutical Technology Co., Ltd. (上海青潤醫藥科技有限公司) between November 2016 and August 2018.

Ms. Wang received her master's degree in pharmaceutical technology from King's College London in the United Kingdom in November 2016. She obtained a board secretary qualification from the Shanghai Stock Exchange in December 2020.

Ms. Wang indirectly holds 120,200 A shares of the Company through Ningbo Meishan Free Trade Port Zhongjun Jianlong Investment Partnership (Limited Partnership) (寧波梅山保税港區中駿建隆投資合夥企業(有限合夥)).

According to the service contract entered between the Company and Dr. Liu Datao, Dr. Liu Datao will receive remuneration from the Company in accordance with his positions held in the Company, which will be determined in accordance with the remuneration management system for Directors and senior management. The Company will disclose the remuneration of the Directors in its annual report.

As at the date of this announcement, save as disclosed above, each of Dr. Liu Datao, Dr. Wu Hai, Mr. Hua Jun, Dr. Gui Xun, Dr. Wang Shuhai, Mr. Hu Huiguo, Mr. Li Han, Mr. Ni Hua, Ms. Chen Xi, Ms. Yu Shanshan, and Ms. Wang Hefei confirms that: (i) he/she does not have any relationship with any directors, supervisors, senior management, substantial shareholders or controlling shareholder of the Company or its subsidiaries or have other major appointments and professional qualifications; (ii) he/she does not hold any other position in the Company or its subsidiaries and did not hold any directorship or supervisorship in any other companies listed in Hong Kong or overseas in the last three years; (iii) he/she does not have or is not deemed to have any interests in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance; and (iv) there is no other matter with respect to his/her appointment that needs to be brought to the attention of the shareholders of the Company or the Hong Kong Stock Exchange or that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

By Order of the Board
Mabwell (Shanghai) Bioscience Co., Ltd.
Dr. Liu Datao
Chairman of the Board and Executive Director

Shanghai, the PRC, June 18, 2026

As at the date of this announcement, the directors of the Company are: (i) Mr. Tang Chunshan, Dr. Liu Datao (Chairman of the Board), Dr. Wu Hai, Mr. Hua Jun and Dr. Gui Xun as executive directors; and (ii) Mr. Qin Zhengyu, Mr. Zhou Rui, Ms. Li Fan and Ms. Wang Fang as independent non-executive directors.